Evaluation of the Roche prototype 454 HIV-1 ultradeep sequencing drug resistance assay in a routine diagnostic laboratory

Journal of Clinical Virology

Volumn 58, Issue 2, 2013, Pages 468-473

  Garcia Diaz, A ^a   Guerrero Ramos, A ^a   McCormick, A L ^a   Macartney, M ^a   Conibear, T ^a   Johnson, M A ^a   Haque, T ^a   Webster, D P ^a  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

454; HIV; Resistance; UDS

Indexed keywords

ABACAVIR; DARUNAVIR; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; DRUG RESISTANCE; GENE FREQUENCY; HIGH THROUGHPUT SEQUENCING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RESISTANCE ASSOCIATED MUTATION; RETROSPECTIVE STUDY; STANDARD; TREATMENT OUTCOME; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

454; HIV; RESISTANCE; UDS;

DRUG RESISTANCE, VIRAL; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV INFECTIONS; HIV-1; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; PLASMA; RETROSPECTIVE STUDIES; RNA, VIRAL;

EID: 84884530557     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2013.07.009     Document Type: Article

References (26)

1. Tural C., Ruiz L., Holtzer C., Schapiro J., Viciana P., Gonzalez J., et al. Clinical utility of HIV-1 genotyping and expert advice: the havana trial. AIDS 2002, 16:209-218.
2. Durant J., Clevenbergh P., Halfon P., Delgiudice P., Porsin S., Simonet P., et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. The Lancet 1999, 353:2195-2199.
3. Baxter J.D., Mayers D.L., Wentworth D.N., Neaton J.D., Hoover M.L., Winters M.A., et al. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 2000, 14:F83-F93.
4. Asboe D., Aitken C., Boffito M., Booth C., Cane P., Fakoya A., et al. British HIV Association guidelines for the routine investigations and monitoring of adult HIV-1 infected individuals 2011. HIV Med 2012, 13:1-44.
5. Clumeck N., Pozniak A., Raffi F., the EACS Executive Committee European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008, 9:65-71.
6. Palmer S., Kearney M., Malderelli F., Halvas E.K., Bixby C.J., Bazmi H., et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotypes analysis. J Clin Microbiol 2005, 43:406-413.
7. Johnson J.A., Li J.F., Wei X., Lipscomb J., Irlbeck D., Craig C., et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment naive populations and associated with reduced treatment efficacy. PLoS Med 2008, 5:e158.
8. Metzner K.J., Giulieri S.G., Knoepfel S.A., Rauch P., Burgisser P., Yerly S., et al. Minority quasispecies of drug resistant HIV-1 that lead to early therapy failure in treatment-naive and-adherence patients. Clin Infect Dis 2009, 48:239-247.
9. Geretti A.M., Fox Z.V., Booth C.L., Smith C.J., Phillips A.J., Johnson M., et al. Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2009, 52:569-573.
10. Li J.Z., Paredes R., Ribaudo H.J., Svaroskaia E.S., Metzner K.J., Kozal M.J., et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA 2011, 305:1327-1335.
11. Wang C., Mitsuya Y., Gharizadeh B., Ronaghi M., Shafer R.W. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res 2007, 17(8):1195-1201.
12. Margulies M., Egholm M., Altman W.E., Attiya S., Bader J.S., Bemben L.A., et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005, 437:376-380.
13. Barzon L., Lavezzo E., Militello V., Toppo S., Palu G. Applications of next-generation sequencing technologies to diagnostic virology. Int J Mol Sci 2011, 12:7861-7884.
14. Garcia-Diaz A., Labbett W., Clewley G.S., Guerrero-Ramos, Geretti A.M. Comparative evaluation of the Artus HIV-1 QS-RGQ assay and the Abbott RealTime HIV-1 assay for the quantification of HIV-1 RNA in plasma. J Clin Virol 2013, 57(1):66-69.
15. Booth C.L., Garcia-Diaz A.M., Youle M.S., Johnson M.A., Phillips A., Geretti A.M. Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection. J Antimicrob Chemother 2007 Mar, 59(3):517-524.
16. Boaz A., Girshengorn S., Matus N., Hadass T., Achsanov S., Zeldis I., et al. Evaluation of a benchtop HIV ultradeep pyrosequencing drug resistance assay in the clinical laboratory. J Clin Microbiol 2013, 51(3):880-886.
17. Stelz E., Proll J., Bizon B., Niklas N., Danzer M., Hackl C., et al. Human immunodeficiency virus type 1 drug resistance testing: evaluation of a new ultra-deep sequencing-based protocol and comparison with TRUGENE HIV-1 Genityping Kit. J Virol Methods 2011 Dec, 178:94-97.
18. Mackie E.N., Dustans S., McClure M.J., Weber J.N., Clartre J.R. Detection of HIV-1 antiretroviral drug resistance from patients with persistently low but detectable viremia. J Virol Methods 2004, 119:73-81.
19. Mackie E.N., Phillips A.N., Kaye S., Booth C., Geretti A.M., on behalf of the UK HIV drug resistance database and the UK collaborative HIV cohort study Antiretroviral drug resistance in HIV-1infected patients at low-level viremia. J Infect Dis 2010, 201:1303-1307.
20. Huse S.M., Huber J.A., Morrison H.G., Sogin M.L., Welch D.M. Accuracy and quality of massively parallel DNA pyrosequencing. Genome Biol 2007, 8:R143.
21. Varghese V., Wang E., Babrzadeh F., Bachman M.H., Shahriar R., et al. Nucleic acid template and the risk of a PCR-induced HIV-1 drug resistance mutation. Plos One 2010, 5. doi: 10.1371/journal.pone.0010992.
22. Gilles A., Meglecz E., Pech N., Ferreira S., Malausa T., et al. Accuracy and quality assessment of 454 GS-FLX Titanium pyrosequencing. BMC Genomics 2011, 12:245.
23. Shao W., Boltz V.F., Spindler J.E., Keraney M.F., Maldarelli F., et al. Analysis of 454 sequencing error rate, error sources, and artefact recombination for detection of Low-frequency drug resistance mutations in HIV-1 DNA. Retrovirology 2013 Feb 13, 18:10.
24. Simen B.B., Simons J.F., Hullsiek K.H., Novak R.M., Macarthur R.D., et al. Low-abundance drug-resistant viral variants in chronically HIV-infected antiretroviral-naïve patients significantly impact treatment outcomes. J Infect Dis 2009 Mar 1, 199(5):693-701.
25. Paredes R., Lalama C.M., Ribaudo H.J., Schackman B.R., Shikuma C., Giguel F., et al. Preexisting minority drug-resistant HIV-1 variants, adherence and risk of antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 2010, 50:566-573.
26. Li J.Z., Paredes R., Ribaudo H.J., Kozal M.J., Svarovskaia E.S., Johnson J.A., et al. Impact of minorit nonnucleoside reverse transcriptase inhibitor resistance mutations on resistance genotype after virologic failure. J Infect Dis 2013, 207:893-897.